Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1

Rolando M VianiDepartment of Pediatrics, Division of Infectious Diseases, Center for AIDS Research, University of California San Diego School of Medicine and UCSD, Mother, Child and Adolescent HIV Program, Rady Children&rsquo;s Hospital, San Diego, California, USAAbstract: Etravirine is an o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Rolando M Viani
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/cf761b27dbb44261ac8c579f92071566
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cf761b27dbb44261ac8c579f92071566
record_format	dspace
spelling	oai:doaj.org-article:cf761b27dbb44261ac8c579f920715662021-12-02T01:31:25ZRole of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 11179-1373https://doaj.org/article/cf761b27dbb44261ac8c579f920715662010-06-01T00:00:00Zhttp://www.dovepress.com/role-of-etravirine-in-the-management-of-treatment-experienced-patients-a4670https://doaj.org/toc/1179-1373Rolando M VianiDepartment of Pediatrics, Division of Infectious Diseases, Center for AIDS Research, University of California San Diego School of Medicine and UCSD, Mother, Child and Adolescent HIV Program, Rady Children&rsquo;s Hospital, San Diego, California, USAAbstract: Etravirine is an oral diarylpyrimidine compound, a second-generation human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI) with expanded antiviral activity against NNRTI-resistant HIV-1, to be used in combination therapy for treatment-experienced patients. Compared with first-generation NNRTIs, etravirine has a high genetic barrier to resistance, and is better tolerated without the neuropsychiatric and hepatic side effects of efavirenz and nevirapine, respectively. Its safety profile is comparable to placebo with the exception of rash, which has been mild and self-limited in the great majority of patients. In phase III clinical trials among treatment-experienced patients harboring NNRTI-resistant HIV-1, etravirine in combination with an optimized background regimen (OBR) that included ritonavir-boosted darunavir demonstrated superior antiviral activity than the control OBR. In addition, patients on the etravirine arm had fewer AIDS-defining conditions, hospitalizations, and lower mortality compared with the OBR control arm.Keywords: HIV, antiretroviral therapy, non-nucleoside reverse transcriptase inhibitor Rolando M VianiDove Medical PressarticleImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol 2010, Iss default, Pp 141-149 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607
spellingShingle	Immunologic diseases. Allergy RC581-607 Rolando M Viani Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1
description	Rolando M VianiDepartment of Pediatrics, Division of Infectious Diseases, Center for AIDS Research, University of California San Diego School of Medicine and UCSD, Mother, Child and Adolescent HIV Program, Rady Children&rsquo;s Hospital, San Diego, California, USAAbstract: Etravirine is an oral diarylpyrimidine compound, a second-generation human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI) with expanded antiviral activity against NNRTI-resistant HIV-1, to be used in combination therapy for treatment-experienced patients. Compared with first-generation NNRTIs, etravirine has a high genetic barrier to resistance, and is better tolerated without the neuropsychiatric and hepatic side effects of efavirenz and nevirapine, respectively. Its safety profile is comparable to placebo with the exception of rash, which has been mild and self-limited in the great majority of patients. In phase III clinical trials among treatment-experienced patients harboring NNRTI-resistant HIV-1, etravirine in combination with an optimized background regimen (OBR) that included ritonavir-boosted darunavir demonstrated superior antiviral activity than the control OBR. In addition, patients on the etravirine arm had fewer AIDS-defining conditions, hospitalizations, and lower mortality compared with the OBR control arm.Keywords: HIV, antiretroviral therapy, non-nucleoside reverse transcriptase inhibitor
format	article
author	Rolando M Viani
author_facet	Rolando M Viani
author_sort	Rolando M Viani
title	Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1
title_short	Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1
title_full	Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1
title_fullStr	Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1
title_full_unstemmed	Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1
title_sort	role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/cf761b27dbb44261ac8c579f92071566
work_keys_str_mv	AT rolandomviani roleofetravirineinthemanagementoftreatmentexperiencedpatientswithhumanimmunodeficiencyvirustype1
_version_	1718403041937326080

Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1

Ejemplares similares